SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently trending as investors focus on its post-quantum cryptography features and recent institutional developments, including its classification as a digital commodity. While the community remains deeply divided between long-term holders citing technological utility and skeptics reacting to extended price consolidation, discussion is heavily driven by recent Google research citations and strategic moves toward real-world asset tokenization.

APE fuels culture. Backed by the best club in the world and hundreds of thousands of holders worldwide, it’s the token for digital and IRL communities, builders, creators, collectors, gamers, and beyond.  APE is the native gas token of ApeChain and is available across multiple ecosystems including Ethereum, Arbitrum, Solana and HyperLiquid.z  ApeCoin's mission is is to supercharge its ecosystem by supporting high-quality builders &amp; reinforcing 3 core pillars: ApeChain, Bored Ape Yacht Club, and Otherside.

ApeCoin

ApeCoin is seeing a surge in investor attention as market sentiment shifts toward a potential crypto bull cycle and anticipation builds for continued network utility and ecosystem growth. The community is actively debating the token's long-term viability, with many closely watching volume spikes and technical resistance levels for signs of a parabolic trend.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community rallies around its long-standing presence on the Solana network, emphasizing its inclusion on the Jupiter strict list and active engagement through community poker events. Supporters are highlighting the token's resilience after years of operation while actively promoting it across social channels to sustain its visibility among other trending meme coins.

The Sandbox is a community-driven platform where creators can monetize voxel ASSETS and gaming experiences on the blockchain.  SAND is the utility token used throughout The Sandbox ecosystem as the basis of transactions and interactions. It is an ERC-20 utility token built on the Ethereum blockchain. There is a finite supply of 3,000,000,000 SAND.

The Sandbox

The Sandbox is seeing renewed investor interest as gaming tokens heat up, fueled by a broader crypto market revival and anticipation of a metaverse resurgence. Community members are actively discussing potential price appreciation, drawing parallels to historical bull cycles while focusing on the project's long-standing partnerships and ecosystem development as key indicators for future performance.

Index Coop is a decentralized autonomous organization (DAO) that builds structured DeFi products and strategy tokens. Index Coop offers a suite of sector index products, leverage and inverse products, and yield-generating products. The product suite runs on Set Protocol, an audited, self-custodial DeFi tool that allows for the creation and management of Ethereum-based (or ERC-20) tokens. Changes to the DAO are voted on by the owners of a governance token called INDEX and then implemented by a team of developers. INDEX holders wield voting power on a 1:1 basis, meaning one token equals one vote.

Index Cooperative

Index Cooperative is seeing a surge in community engagement and speculation regarding its potential as a low-float asset primed for significant volatility, with many users drawing parallels to previous market cycles. Community discussions are heavily focused on the low circulating supply and its historical tendency for rapid price swings, while some participants debate the long-term utility of the governance token and its role in upcoming decentralized finance product expansions.

Polygon

Polygon is trending as investors debate whether the network's high transaction volume and adoption in stablecoin payments justify its current market performance or signal a deep undervaluation. The community remains polarized, with some bulls aggressively accumulating, citing the shift to the 'Open Money Stack' and payment-focused infrastructure, while others express frustration over continued price stagnation and concerns about dilution.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors weigh significant clinical catalysts, including upcoming Phase 3 data and potential FDA updates, against a high level of short interest that has fueled aggressive community debate over a possible short squeeze. While some traders are focused on the stock's volatility and the prospect of a major rebound, others remain cautious, debating the long-term impact of recent capital raises and the broader outlook for the gene-editing sector.

VeChain, founded in 2015, is a sustainability-focused blockchain driving mass adoption of Web3. Its energy-efficient VeChainThor chain delivers fast, low-cost transactions, making blockchain accessible to millions worldwide. With partnerships including UFC, BCG, and Walmart, and over 2 million active users on VeBetter-powered apps, VeChain is proving real-world impact at scale.  In 2024, the VeChain Renaissance upgrade was launched, introducing Ethereum compatibility, dPoS consensus, and dynamic gas fees. It cut VTHO inflation and introduced StarGate NFT staking, where users lock VET to mint transferable NFTs that earn VTHO, can be delegated to validators, and serve as governance instruments. The upgrade also added new eco node tiers, lowering entry barriers while keeping rewards across higher staking levels.  By combining adoption, upgraded tokenomics, and inclusive staking, VeChain is positioning itself as a leading blockchain where usage, growth, and rewards fuel long-term value creation.

Vechain

VeChain is trending as the community debates its long-term viability amid ongoing price stagnation and concerns over treasury management versus the project's extensive corporate and regulatory partnerships. While some investors are actively accumulating and pointing to upcoming protocol upgrades and supply chain utility as catalysts, others remain deeply frustrated by the asset's poor performance relative to the broader crypto market.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF

JEPQ remains a focal point for income-focused investors who are actively debating its performance relative to peers like QQQI and SPYI, especially as the community balances tech-heavy growth potential against the consistency of monthly distributions. Conversations are heavily concentrated on dividend capture strategies and the long-term role of the ETF within retirement portfolios, with many investors debating the tax implications of these distributions in taxable versus tax-advantaged accounts.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Equity Premium Income ETF

JPMorgan Equity Premium Income ETF

JPMorgan's JEPI and JEPQ are seeing heavy community interest due to their consistent monthly cash flow and defensive structure, which many investors are using to navigate current market volatility. While some participants discuss recent dividend distribution amounts and the role of covered call overlays in stabilizing portfolios, the community remains divided between those prioritizing long-term income accumulation and those concerned about the impact of market fluctuations on net asset value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Torray Investment Partners LLC Invests $2.06 Million in Syndax Pharmaceuticals, Inc. $SNDX

Torray Investment Partners LLC purchased a new position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) in the 4th quarter, according to the company in its most recent...

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fourteen ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has as...

Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 52-Week High  - Should You Buy?

Syndax Pharmaceuticals (NASDAQ:SNDX) Sets New 12-Month High - Time to Buy...

Palumbo Wealth Management LLC Invests $1.08 Million in Syndax Pharmaceuticals, Inc. $SNDX

Palumbo Wealth Management LLC purchased a new position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with...

SG Americas Securities LLC Has $2.72 Million Stock Position in Syndax Pharmaceuticals, Inc. $SNDX

SG Americas Securities LLC raised its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 184.5% during the 4th quarter, according to its most recent disclosure with the...

Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says

The Goldman Sachs Group increased their target price on shares of Syndax Pharmaceuticals from $28.00 to $34.00 and gave the stock a "buy" rating in a research report on Wednesday...

Syndax Pharmaceuticals, Inc. $SNDX Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. trimmed its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 97.7% in the fourth quarter, according to the company in its most recent...

Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Cut to $43.00 by Analysts at Mizuho

Mizuho decreased their target price on Syndax Pharmaceuticals from $45.00 to $43.00 and set an "outperform" rating on the stock in a research note on Tuesday...

Hennion & Walsh Asset Management Inc. Grows Stake in Syndax Pharmaceuticals, Inc. $SNDX

Hennion & Walsh Asset Management Inc. grew its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 236.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned...

Jefferies Financial Group Reiterates "Buy" Rating for Syndax Pharmaceuticals (NASDAQ:SNDX)

Jefferies Financial Group reissued a "buy" rating and set a $40.00 price target (down from $48.00) on shares of Syndax Pharmaceuticals in a research note on Monday...

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

SNDX
Syndax Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SNDX News

SNDXSyndax Pharmaceuticals Inc